CTCL
MCID: CTN015
MIFTS: 48

Cutaneous T Cell Lymphoma (CTCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

MalaCards integrated aliases for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 12 15
Cutaneous T-Cell Lymphoma 12 73 20 17
Lymphoma, T-Cell, Cutaneous 44 70
Lymphoma T-Cell Cutaneous 54
Ctcl 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0060061
MeSH 44 D016410
ICD10 32 C84.8
UMLS 70 C0079773

Summaries for Cutaneous T Cell Lymphoma

GARD : 20 Cutaneous T- cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells ) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known as non-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sezary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.

MalaCards based summary : Cutaneous T Cell Lymphoma, also known as cutaneous t-cell lymphoma, is related to primary cutaneous t-cell lymphoma and lymphoma, non-hodgkin, familial. An important gene associated with Cutaneous T Cell Lymphoma is MIA2 (MIA SH3 Domain ER Export Factor 2), and among its related pathways/superpathways are Akt Signaling and PEDF Induced Signaling. The drugs Denileukin diftitox and Methoxsalen have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and liver.

Disease Ontology : 12 A non-Hodgkin's lymphoma that has material basis in a mutation of T cells.

Wikipedia : 73 Cutaneous T cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the... more...

Related Diseases for Cutaneous T Cell Lymphoma

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous B-Cell Lymphoma Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma
Primary Cutaneous T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous t-cell lymphoma 32.6 TNFRSF8 IL2RA
2 lymphoma, non-hodgkin, familial 32.0 TNFRSF8 MIA2 IL2RA IL2 IL15
3 mycosis fungoides 31.7 TNFRSF8 TIA1 IL2RA IL2 IL15 IFNA1
4 sezary's disease 31.7 TNFRSF8 TIA1 IL2RA IL2 IL15 IFNA1
5 contact dermatitis 31.2 IL2 IL15 CCR4 CCR10
6 lymphopenia 31.2 IL2RA IL2 IL15
7 t-cell lymphoblastic leukemia/lymphoma 31.1 TNFRSF8 IL2RA IL2 CCR4
8 dermatitis, atopic 31.1 TNFRSF8 IL2RA IL2 CCR4
9 lymphomatoid papulosis 31.0 TNFRSF8 TIA1
10 psoriasis 30.9 IL2RA IL2 IL15 CCR4 CCR10
11 lymphoma 30.9 ZNF638 ZMYND8 TNFRSF8 TIA1 MIA2 IL2RA
12 acquired immunodeficiency syndrome 30.9 IL2RA IL2 IL15 IFNA1
13 peripheral t-cell lymphoma 30.9 TNFRSF8 TIA1 IL2 CCR4
14 adult t-cell leukemia 30.9 TNFRSF8 IL2RA IL2 IL15 IFNA1 CCR4
15 hypereosinophilic syndrome 30.9 IL2RA IL2 IFNA1
16 t-cell lymphoma, subcutaneous panniculitis-like 30.8 TNFRSF8 TIA1
17 allergic contact dermatitis 30.8 IL2RA CCR4 CCR10
18 anaplastic large cell lymphoma 30.8 TNFRSF8 TIA1 IL2RA CCR4
19 skin disease 30.7 TNFRSF8 TIA1 IL2 IFNA1 CCR10
20 autoimmune disease 30.7 IL2RA IL2 IL15 IFNA1 CCR4
21 panniculitis 30.7 TNFRSF8 TIA1 IL2RA
22 fixed drug eruption 30.6 IL2 CCR4
23 lymphoproliferative syndrome 30.6 TNFRSF8 TIA1 IL2RA IL2
24 leukemia, chronic lymphocytic 30.6 TNFRSF8 IL2RA IL2 IFNA1 HDAC9
25 lymphoma, hodgkin, classic 30.5 TNFRSF8 TIA1 IL2RA IL2 CCR4
26 tropical spastic paraparesis 30.5 IL2RA IL2 IL15
27 hairy cell leukemia 30.4 IL2RA IL2 IFNA1
28 immune deficiency disease 30.3 TNFRSF8 IL2RA IL2 IL15 IFNA1 CCR4
29 t-cell adult acute lymphocytic leukemia 30.3 TNFRSF8 TIA1 IL2RA IL2 CCR4
30 lymphomatoid granulomatosis 30.2 TIA1 IFNA1
31 angioimmunoblastic t-cell lymphoma 30.2 TNFRSF8 TIA1 IL2RA
32 mature t-cell and nk-cell lymphoma 30.1 TNFRSF8 TIA1 MIA2 IL2 HDAC9
33 multiple sclerosis 30.0 IL2RA IL2 IL15 IFNA1 CCR4
34 pfeiffer syndrome 30.0 TNFRSF8 IL2 IL15
35 celiac disease 1 30.0 TIA1 IL2RA IL2 IL15
36 hematologic cancer 29.8 TNFRSF8 IL2RA IL2 HDAC9
37 composite lymphoma 29.7 TNFRSF8 TIA1
38 hydroa vacciniforme-like lymphoma 11.5
39 parapsoriasis 11.3
40 aggressive primary cutaneous t-cell lymphoma 11.3
41 indolent primary cutaneous t-cell lymphoma 11.3
42 granulomatous slack skin disease 11.3
43 dermatitis 10.7
44 b-cell lymphoma 10.7
45 leukemia, t-cell, chronic 10.7
46 graft-versus-host disease 10.6
47 alopecia 10.6
48 diphtheria 10.6
49 neutropenia 10.6
50 exanthem 10.6

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to Cutaneous T Cell Lymphoma

Symptoms & Phenotypes for Cutaneous T Cell Lymphoma

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
2
Methoxsalen Approved Phase 4 298-81-7 4114
3 Clorazepate Dipotassium Phase 4
4 Pharmaceutical Solutions Phase 4
5 Photosensitizing Agents Phase 4
6 Dermatologic Agents Phase 4
7 Interferon alpha-2 Phase 4
8 Interferon-alpha Phase 4
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
10
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
11
Lenalidomide Approved Phase 3 191732-72-6 216326
12
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
13
Hypericin Investigational Phase 3 548-04-9 5281051
14 Narcotics Phase 3
15 Opiate Alkaloids Phase 3
16 Narcotic Antagonists Phase 3
17 Antidepressive Agents Phase 3
18 Psychotropic Drugs Phase 3
19 Immunologic Factors Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Antibodies Phase 3
22 Immunoglobulins Phase 3
23 Antibodies, Monoclonal Phase 3
24 Antineoplastic Agents, Immunological Phase 3
25 Zanolimumab Phase 3
26
Tazarotene Approved, Investigational Phase 1, Phase 2 118292-40-3 5381
27
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
28
Melphalan Approved Phase 2 148-82-3 4053 460612
29
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
30
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
32
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
35
Adenosine Approved, Investigational Phase 2 58-61-7 60961
36
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
37
Lenograstim Approved, Investigational Phase 2 135968-09-1
38
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
39
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
40
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
41
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
42
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
43
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
44
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
45
Ondansetron Approved Phase 2 99614-02-5 4595
46
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
47
Methylcobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4
48
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 11953898 15589840
49
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
50
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137

Interventional clinical trials:

(show top 50) (show all 281)
# Name Status NCT ID Phase Drugs
1 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
2 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
3 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
4 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
5 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
6 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
7 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
8 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
9 A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
10 A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor Completed NCT00490776 Phase 2, Phase 3 LBH589
11 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
12 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
13 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma Recruiting NCT01871727 Phase 3 E7777 9 mcg/kg
14 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
15 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Active, not recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
16 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma Active, not recruiting NCT01728805 Phase 3 Vorinostat
17 A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma Terminated NCT01098656 Phase 3 lenalidomide
18 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
19 Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study. Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
20 A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT) Unknown status NCT02542124 Phase 2
21 A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma Unknown status NCT02213861 Phase 2 SHAPE
22 Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Unknown status NCT01132989 Phase 2 Lenalidomide
23 Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Unknown status NCT00779896 Phase 1, Phase 2 Tazarotene
24 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Unknown status NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
25 A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
26 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial Unknown status NCT02943642 Phase 2 Vorinostat
27 Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Unknown status NCT02881749 Phase 2 mechlorethamine gel 0.016%
28 A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma Unknown status NCT03239392 Phase 1, Phase 2 BNZ132-1-40
29 Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00501735 Phase 2 Forodesine 200 mg
30 A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA Completed NCT03292406 Phase 2 Placebo;CD11301 0.03%;CD11301 0.06%
31 Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00061880 Phase 1, Phase 2 forodesine hydrochloride
32 A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00182637 Phase 2 bortezomib
33 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
34 Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00506129 Phase 2 Fludarabine;Melphalan;Thymoglobulin
35 Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells Completed NCT00099593 Phase 2
36 Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Completed NCT00306969 Phase 1, Phase 2 bexarotene
37 Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Completed NCT00071084 Phase 2 HuMax-CD4
38 Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. Completed NCT00071071 Phase 2 HuMax-CD4
39 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866
40 Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
41 A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma Completed NCT00106431 Phase 2 romidepsin (depsipeptide, FK228)
42 Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
43 Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
44 A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma Completed NCT01676831 Phase 1, Phase 2 Topical resiquimod 0.06%;topical resiquimod 0.03%
45 A Prospective, Multi-center, Open-label, Single-arm, Phase II Study of Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma Completed NCT03487133 Phase 2 bortezomib/dexamethasone
46 A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma Completed NCT00744991 Phase 2 Enzastaurin
47 A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma Completed NCT00043420 Phase 1, Phase 2 PF-3512676;PF-3512676;PF-3512676;PF-3512676;PF-3512676;PF-3512676;PF-3512676;PF-3512676
48 A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Completed NCT01486277 Phase 2 Quisinostat, 12 mg
49 Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma Completed NCT00030849 Phase 2 bexarotene
50 A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


bexarotene
DENILEUKIN

Cochrane evidence based reviews: lymphoma, t-cell, cutaneous

Genetic Tests for Cutaneous T Cell Lymphoma

Anatomical Context for Cutaneous T Cell Lymphoma

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

40
Skin, T Cells, Liver, Bone Marrow, Lymph Node, Myeloid, Endothelial

Publications for Cutaneous T Cell Lymphoma

Articles related to Cutaneous T Cell Lymphoma:

(show top 50) (show all 4137)
# Title Authors PMID Year
1
STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. 61 54
20213502 2010
2
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. 54 61
20308564 2010
3
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. 61 54
20212249 2010
4
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. 54 61
20132536 2010
5
HDAC inhibitors in cancer care. 61 54
20361469 2010
6
Histone deacetylase inhibitors in cancer therapy. 61 54
19826124 2009
7
Histone deacetylase inhibitors: current status and overview of recent clinical trials. 61 54
19747008 2009
8
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. 61 54
19220424 2009
9
Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. 54 61
19242508 2009
10
Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. 54 61
18923451 2009
11
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. 54 61
19344187 2009
12
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. 61 54
19689336 2009
13
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. 61 54
18839006 2008
14
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. 61 54
18496567 2008
15
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 54 61
19239991 2008
16
Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. 54 61
18838793 2008
17
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. 54 61
18671804 2008
18
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. 61 54
18569641 2008
19
Novel purine nucleoside analogues for hematological malignancies. 61 54
18537755 2008
20
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. 54 61
18281483 2008
21
Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations. 61 54
17597825 2007
22
Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. 54 61
18086344 2007
23
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. 61 54
18021470 2007
24
Trithiocarbonates: exploration of a new head group for HDAC inhibitors. 54 61
17606370 2007
25
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. 54 61
17594194 2007
26
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. 61 54
17367611 2007
27
Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma. 61 54
17340017 2007
28
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? 61 54
17109024 2007
29
Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. 61 54
16673127 2006
30
Immunotoxins for targeted cancer therapy. 61 54
17025272 2006
31
Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. 54 61
16859899 2006
32
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 61 54
16741518 2006
33
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. 61 54
16645590 2006
34
Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. 61 54
16830050 2006
35
[Extensive cutaneous candidiasis revealing cutaneous T-cell lymphoma: 2 cases]. 61 54
16885846 2006
36
The influence of STAT5 antisense oligodeoxynucleotides on the proliferation and apoptosis of selected human cutaneous T-cell lymphoma cell lines. 61 54
16502315 2006
37
Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. 61 54
16322477 2006
38
CCR10 is expressed in cutaneous T-cell lymphoma. 54 61
15700309 2005
39
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. 54 61
15727636 2005
40
Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma. 54 61
16088151 2005
41
Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells. 61 54
15542358 2004
42
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. 61 54
15328153 2004
43
Recombinant immunotoxins for the treatment of haematological malignancies. 54 61
15268678 2004
44
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. 61 54
15141228 2004
45
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. 54 61
15243520 2004
46
Extracorporeal photopheresis differentially regulates the expression of phosphorylated STAT-1 and STAT-5 in treated monocytes and T cells, respectively. 61 54
15578129 2004
47
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 61 54
14710894 2003
48
Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. 61 54
12841391 2003
49
Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. 61 54
12754746 2003
50
CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients. 54 61
12675243 2003

Variations for Cutaneous T Cell Lymphoma

Copy number variations for Cutaneous T Cell Lymphoma from CNVD:

7 (show all 49)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21732 1 16100000 20300000 Amplification Cutaneous T-cell lymphoma
2 25426 1 189000000 192100000 Deletion Cutaneous T-cell lymphoma
3 38869 10 105700000 111800000 Deletion Cutaneous T-cell lymphoma
4 39996 10 12300000 17300000 Deletion Cutaneous T-cell lymphoma
5 41377 10 17300000 19900000 Amplification Cutaneous T-cell lymphoma
6 42285 10 31400000 34500000 Deletion Cutaneous T-cell lymphoma
7 47113 10 89600000 92900000 Deletion PTEN Cutaneous T-cell lymphoma
8 61605 12 10000000 12600000 Deletion ETV6 Cutaneous T-cell lymphoma
9 71417 12 69800000 74100000 Deletion Cutaneous T-cell lymphoma
10 77639 13 46200000 48900000 Deletion RB1 Cutaneous T-cell lymphoma
11 83022 14 19100000 23600000 Deletion NDRG2 Cutaneous T-cell lymphoma
12 83023 14 19100000 23600000 Deletion ZNF219 Cutaneous T-cell lymphoma
13 97437 16 10300000 12500000 Deletion Cutaneous T-cell lymphoma
14 98274 16 16700000 20500000 Deletion Cutaneous T-cell lymphoma
15 107006 17 11200000 15900000 Deletion MAP2K4 Cutaneous T-cell lymphoma
16 108845 17 23200000 28800000 Amplification DHRS13 Cutaneous T-cell lymphoma
17 108846 17 23200000 28800000 Amplification ERAL1 Cutaneous T-cell lymphoma
18 108847 17 23200000 28800000 Amplification FLOT2 Cutaneous T-cell lymphoma
19 108848 17 23200000 28800000 Amplification PHF12 Cutaneous T-cell lymphoma
20 112029 17 37800000 41900000 Amplification Cutaneous T-cell lymphoma
21 116538 17 6800000 11200000 Deletion TP53 Cutaneous T-cell lymphoma
22 120627 18 2900000 7200000 Amplification Cutaneous T-cell lymphoma
23 123359 18 71300000 76117153 Deletion PARD6G Cutaneous T-cell lymphoma
24 133686 19 6900000 12600000 Deletion Cutaneous T-cell lymphoma
25 142291 2 221300000 224900000 Deletion Cutaneous T-cell lymphoma
26 152036 20 28400000 31500000 Amplification BCL2L1 Cutaneous T-cell lymphoma
27 162458 22 21800000 24300000 Amplification Cutaneous T-cell lymphoma
28 162461 22 21800000 24300000 Deletion Cutaneous T-cell lymphoma
29 171538 3 169200000 172500000 Amplification PRKCI Cutaneous T-cell lymphoma
30 180261 4 102500000 107900000 Amplification Cutaneous T-cell lymphoma
31 180582 4 107900000 114100000 Amplification Cutaneous T-cell lymphoma
32 181002 4 114100000 120600000 Amplification Cutaneous T-cell lymphoma
33 184833 4 182600000 187300000 Deletion Cutaneous T-cell lymphoma
34 186902 4 40900000 45600000 Deletion Cutaneous T-cell lymphoma
35 190065 4 82600000 84300000 Deletion Cutaneous T-cell lymphoma
36 203973 6 104800000 113900000 Deletion Cutaneous T-cell lymphoma
37 206027 6 135200000 139100000 Deletion Cutaneous T-cell lymphoma
38 211016 6 31900000 33600000 Deletion Cutaneous T-cell lymphoma
39 212690 6 40600000 45200000 Deletion VEGFA Cutaneous T-cell lymphoma
40 222425 7 15200000 19500000 Deletion Cutaneous T-cell lymphoma
41 225996 7 53900000 57400000 Amplification EGFR Cutaneous T-cell lymphoma
42 233736 8 127300000 131500000 Amplification MYC Cutaneous T-cell lymphoma
43 237881 8 27400000 29700000 Deletion Cutaneous T-cell lymphoma
44 238080 8 29700000 38500000 Deletion Cutaneous T-cell lymphoma
45 239603 8 39900000 43200000 Deletion Cutaneous T-cell lymphoma
46 243701 8 87200000 93500000 Amplification Cutaneous T-cell lymphoma
47 244139 8 93500000 99100000 Deletion Cutaneous T-cell lymphoma
48 249980 9 19900000 25500000 Deletion CDKN2A Cutaneous T-cell lymphoma
49 255727 9 83400000 86100000 Deletion Cutaneous T-cell lymphoma

Expression for Cutaneous T Cell Lymphoma

Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for Cutaneous T Cell Lymphoma

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 TNFRSF8 TGFBR1 IL2RA IL2 IL15 CCR4
2
Show member pathways
13.15 TNFRSF8 TGFBR1 IL2RA IL2 IL15 IFNA1
3
Show member pathways
12.87 TNFRSF8 TGFBR1 IL2RA IL2 IL15 CCR4
4 12.62 TGFBR1 IL2RA IL2 IL15 IFNA1
5
Show member pathways
12.6 IL2RA IL2 IL15 IFNA1 CCR10
6 12.35 TNFRSF8 IL2RA IL2 IFNA1
7
Show member pathways
12.18 IL2RA IL2 IL15 IFNA1
8 12.01 TGFBR1 IL2RA IL2 IL15
9
Show member pathways
11.96 IL2RA IL2 CCR4 CCR10
10 11.76 IL2RA IL2 IL15
11
Show member pathways
11.56 TGFBR1 IL2RA IL2 IL15 IFNA1
12 11.51 IL2RA IL2 IL15
13 11.44 IL2RA IL2 IL15
14
Show member pathways
10.36 IL2RA IL2 IL15

GO Terms for Cutaneous T Cell Lymphoma

Cellular components related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum exit site GO:0070971 8.92 MIA2 CTAGE4 CTAGE3P CTAGE1

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.83 IL2RA IL2 IL15 CCR4 CCR10
2 ER to Golgi vesicle-mediated transport GO:0006888 9.67 MIA2 CTAGE4 CTAGE3P CTAGE1
3 positive regulation of T cell proliferation GO:0042102 9.58 IL2RA IL2 IL15
4 positive regulation of T cell differentiation GO:0045582 9.51 IL2RA IL2
5 positive regulation of interleukin-17 production GO:0032740 9.49 IL2 IL15
6 regulation of regulatory T cell differentiation GO:0045589 9.48 IL2RA IL2
7 interleukin-2-mediated signaling pathway GO:0038110 9.46 IL2RA IL2
8 negative regulation of lymphocyte proliferation GO:0050672 9.32 IL2RA IL2
9 positive regulation of tissue remodeling GO:0034105 9.26 IL2 IL15
10 protein secretion GO:0009306 9.26 MIA2 CTAGE4 CTAGE3P CTAGE1
11 regulation of T cell homeostatic proliferation GO:0046013 9.16 IL2RA IL2
12 cargo loading into vesicle GO:0035459 8.92 MIA2 CTAGE4 CTAGE3P CTAGE1

Molecular functions related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine receptor activity GO:0004950 8.62 CCR4 CCR10

Sources for Cutaneous T Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....